000142094 001__ 142094
000142094 005__ 20240229105143.0
000142094 0247_ $$2doi$$a10.1007/s00228-018-2534-1
000142094 0247_ $$2pmid$$apmid:30159676
000142094 0247_ $$2ISSN$$a0031-6970
000142094 0247_ $$2ISSN$$a0369-9498
000142094 0247_ $$2ISSN$$a1432-1041
000142094 0247_ $$2altmetric$$aaltmetric:47239830
000142094 037__ $$aDKFZ-2018-02324
000142094 041__ $$aeng
000142094 082__ $$a610
000142094 1001_ $$0P:(DE-He78)358cd16fe1dd16be6e4eaf0e76e5ad57$$aMuhlack, Dana Clarissa$$b0$$eFirst author$$udkfz
000142094 245__ $$aThe associations of geriatric syndromes and other patient characteristics with the current and future use of potentially inappropriate medications in a large cohort study.
000142094 260__ $$aNew York$$bSpringer$$c2018
000142094 3367_ $$2DRIVER$$aarticle
000142094 3367_ $$2DataCite$$aOutput Types/Journal article
000142094 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1550055331_19512
000142094 3367_ $$2BibTeX$$aARTICLE
000142094 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000142094 3367_ $$00$$2EndNote$$aJournal Article
000142094 520__ $$aTo assess the changes in use of potentially inappropriate medication (PIM) as defined by the 2015 Beers criteria, the EU(7)-PIM, and the PRISCUS list over a 6-year period and to identify determinants for current and future PIM use with a particular focus on geriatric syndromes.In a German cohort of 2878 community-dwelling adults aged ≥ 60 years, determinants of the use of ≥ 1 PIM were identified in multivariable logistic regression (cross-sectional analysis) and weighted generalized estimating equation models (longitudinal analysis).Prevalences for Beers, EU(7), and PRISCUS PIM were 26.4, 37.4, and 13.7% at baseline and decreased to 23.1, 36.5, and 12.3%, respectively, 6 years later. Unadjusted prevalences in participants with any geriatric syndrome (frailty, co-morbidity, functional, or cognitive impairment) were approximately twice as high as in robust older adults. In multivariable analyses, cognitive impairment was statistically significantly associated with the use of PIM of all three criteria in the cross-sectional (odds ratio (OR) point estimates 1.90-2.21) but not in the longitudinal models. In contrast, frailty, co-morbidity, and functional impairment were statistically significantly associated with the use of PIM of at least one of the three criteria in both models. However, the associations varied for the PIM criteria, and in the longitudinal analysis, associations were only statistically significant for Beers PIM (ORs [95% confidence intervals]: frailty (2.23 [1.15, 4.31]), co-morbidity by five total co-morbidity score points (1.21 [1.05, 1.38]), and functional impairment (1.51 [1.00, 2.27]). Other statistically significant determinants of the incidence of PIM (any definition) were female sex, age, coronary heart disease, heart failure, biomarkers of the metabolic syndrome, and history of ulcer, depressive episodes, hip fracture, or any cancer.Older adults with frailty, co-morbidity, cognitive, and functional impairment had higher odds of taking PIM or getting a PIM prescription in the future (exception: cognitive impairment). Physicians should be especially cautious when prescribing drugs for these patients who are particularly susceptible to adverse reactions.
000142094 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000142094 588__ $$aDataset connected to CrossRef, PubMed,
000142094 7001_ $$0P:(DE-He78)747b703d2a306c4276ea9e4ee9b5fe44$$aHoppe, Liesa$$b1$$udkfz
000142094 7001_ $$0P:(DE-He78)908880209a64ea539ae8dc5fdb7e0a91$$aStock, Christian$$b2$$udkfz
000142094 7001_ $$aHaefeli, Walter E$$b3
000142094 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b4$$udkfz
000142094 7001_ $$0P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aSchöttker, Ben$$b5$$eLast author$$udkfz
000142094 773__ $$0PERI:(DE-600)1459058-x$$a10.1007/s00228-018-2534-1$$gVol. 74, no. 12, p. 1633 - 1644$$n12$$p1633 - 1644$$tEuropean journal of clinical pharmacology$$v74$$x1432-1041$$y2018
000142094 909CO $$ooai:inrepo02.dkfz.de:142094$$pVDB
000142094 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000142094 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000142094 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000142094 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000142094 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J CLIN PHARMACOL : 2017
000142094 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000142094 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000142094 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000142094 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000142094 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000142094 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000142094 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000142094 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000142094 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000142094 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000142094 9141_ $$y2018
000142094 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)358cd16fe1dd16be6e4eaf0e76e5ad57$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000142094 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)747b703d2a306c4276ea9e4ee9b5fe44$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000142094 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)908880209a64ea539ae8dc5fdb7e0a91$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000142094 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000142094 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000142094 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000142094 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lKlinische Epidemiologie und Alternsforschung$$x0
000142094 9201_ $$0I:(DE-He78)G110-20160331$$kG110$$lPräventive Onkologie$$x1
000142094 980__ $$ajournal
000142094 980__ $$aVDB
000142094 980__ $$aI:(DE-He78)C070-20160331
000142094 980__ $$aI:(DE-He78)G110-20160331
000142094 980__ $$aUNRESTRICTED